Insmed Shares Dip 2.70% With 349th-Ranked $260M Volume as FDA-Approved Brinsupri Ignites 2035 $15B Sales Outlook and Bullish Technical Signals Emerge

Insmed (INSM) closed 2.70% lower on August 25, 2025, with a trading volume of $260 million, ranking 349th in market activity for the day. Technical indicators showed a KDJ Golden Cross and Bullish Marubozu pattern on the 15-minute chart at 13:00 EDT, signaling potential upward momentum despite the decline. The pattern suggests buyer dominance could drive price recovery in subsequent sessions.

The company recently secured FDA approval for Brinsupri, the first oral treatment for non-cystic fibrosis bronchiectasis (NCFB). This milestone positions Insmed as the sole provider for NCFB, a chronic respiratory condition affecting adults and children aged 12+. The commercial launch of the once-daily therapy is expected to drive long-term revenue growth, supported by its differentiated therapeutic profile.

William Blair analysts initiated coverage with a bullish outlook, projecting $15 billion in peak sales by 2035. Analyst Matt Phipps highlighted the growth potential of Brinsupri, Arikayce, and TPIP, noting that upcoming trial data could unlock new indications. The firm estimates the stock could trade at five times the 2031 revenue forecast of $7.7 billion, reflecting confidence in multi-blockbuster market potential.

A backtested strategy of purchasing top 500 volume-driven stocks and holding for one day generated $2,940 in profits from December 2021 to August 2025. The approach recorded a maximum drawdown of $1,960 and a Sharpe ratio of 1.53. December 2021 was the most profitable month ($840), while August 2025 incurred the largest loss ($790).